Market Research Blog – Page 14640 – New Product Development

Western Blotting Processors Market is enabling it to surpass US$ 383.7 Million in valuation by 2031

From an estimated valuation of US$ 235.5 Mn in 2021, the western blotting processors market is projected to reach a market value of just under US$ 329 Mn towards the close of 2031, exhibiting a decadal CAGR of 11.5%, according to the research report by Future Market Insights.

Conventional western blotting processors are relatively inconsistent in terms of the efficiency of detecting protein traces in samples.

While the technique of western blotting demands time and technical expertise, automation has magnified the process of throughput screening in western blotting, thereby facilitating increasing number of trials and accelerating the experimentation process.

Automated western blotting techniques enable the analysis of several samples at one go, with the only manual task being loading of the sample into the western blotting system.

Automation is currently trending the western blotting processors market, as revealed in a comprehensive research study by Future Market Insights

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-7365

Manufacturers are Accelerating Product Launches and Eyeing Offshoring as a Viable Growth Strategy

The market for western blotting processors is highly competitive with the top companies accounting for a larger part of global sales. Leading companies are acquiring smaller companies and expanding their production capacities to gain a larger share of the global market.

Companies in the western blotting processors market are leveraging the available market opportunities to launch their products in full gear in the global market. One of the market companies leveraged an unexploited demand for point-of-care HIV diagnostics as its key entry strategy in the western blotting processors market.

Product registration followed by commercialisation is accelerating the product launch process and creating healthy competition in the global market for western blotting processors.

Manufacturers of western blotting processors are setting up production facilities in other countries so as to benefit from access to cheap labour and resource expertise, and realign their distribution and customer oriented strategies.

Another key player in the western blotting processors market recently made a strategic investment in the offshore development of its life sciences facility with a mandate to engage in the manufacturing and distribution of molecular biology products to a global clientele.

Increasing Cases of HIV Enabling Western Blotting Processors Market Growth

The number of HIV cases across the world is increasing by the day, causing a burden on the global healthcare industry. Monitoring and controlling the HIV epidemic depends on early detection of anti-HIV antibodies in human blood.

Western blot is a confirmed test that can detect anti-HIV antibodies in blood serum samples. This is one of the factors leading to an increase in the adoption of western blotting processors.

Proteomics is extensively used in the pharmaceuticals industry to identify specific proteins associated with particular diseases, with western blotting finding application in new drug discovery. In the field of medical diagnostics, proteomics is used in the diagnosis of biomarkers that are essentially proteins present in body fluids.

Western blotting helps in quick diagnosis of diseases by identifying proteins that are produced when the human body contracts a disease. Besides the healthcare and pharmaceuticals industry, western blotting also finds application in the agriculture sector to establish protein characterisation in seed quality testing; and in the food and beverages industry to detect whey milk protein in commercial grade soy milk to check for possible adulteration.

Western Blotting Processors Market Growth Challenged by High Costs, Low Innovation, and Unreliability of Automated Devices

Advanced automated western blotting devices such as the high performance western blotting transfer system are highly priced than their traditional counterparts, thereby restricting adoption across several developing economies.

High cost of labour is another challenge in certain regions that continue to carry out protein tests using cheap traditional western blotting processors, thereby leading to time-consuming and high labour cost-inducing processes.

Then again, the global western blotting processors market has not witnessed notable innovation, with very few advanced products launched in recent years.

Further, results obtained from the western blotting process are not fully reliable or consistent and the devices need to be updated regularly to produce more efficient and reliable results. The aforementioned factors are challenging revenue growth of the global western blotting processors market.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-7365

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Disposable Negative Pressure Wound Therapy Devices Market is set to experience significant growth of 10.7% CAGR from 2022 to 2028

In the report published by Future Market Insights titled “Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2013 – 2021) and Opportunity Assessment (2022 – 2028)”, it has been stated that the development around the globe in the last couple of years reflected certain complexities and fissures related to the political environment across many countries.

As protectionists are threatening to penetrate the notions of free-trade, globalization is likely to face its most difficult test ever. The threat of populist policies disrupting the decades-old trade agreements have grown bigger as the social and cultural rift between the bourgeoisie and proletariat is deepening with time.

While the preceding decades were marked by unison and formation of economic blocks, disintegration has been the story of the recent past. Although the business climate is far from favorable for organizations who have interest in multiple countries, the prevailing encounters have also obligated that corporate social responsibility becomes more than just a formality and companies actually demonstrate that they contribute to the societies they operate in.

There is a dire need for companies to participate in discussions and debates that will eventually lead to policy formulations. Owing to these circumstances the global disposable negative pressure wound therapy devices market is anticipated to witness a CAGR of 10.7% over the forecast period of 2022 and 2028.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-6348

Cost Control Measures and Rising Healthcare Expenditure to Bode Well for the Market

The adoption rate of disposable NPWT devices is rising in developed nations such as the U.K., Germany, and the U.S., due to the obligation of healthcare burden across these countries owing to the growing prevalence of chronic wounds. According to an article on Wound Practice and Research, the healthcare expenditure for chronic wounds of 6.5 Mn patients accounts for over US$ 25 Bn per year in the U.S. Other research studies have also indicated that among chronic wounds, venous insufficiency ulcers constitute approximately 50% of the chronic leg ulcers. These wounds result due to venous etiology.

Annual prevalence of venous insufficiency ulcers in those aged 65 and above has been estimated to be near to 2 in every 100 persons per year. Prevalence of pressure ulcers varies between 0.31% and 0.70% per year in the United States. Such cases are likely to boost the demand for disposable NPWT in the years to come.

Moreover, the growing focus on the expenditure pertaining to healthcare across developed as well as developing nations is expected to drive the adoption high quality patient care treatment options across the globe. This has also led to the rise in the per capita healthcare expenditure owing to the rising disposable income of people across the globe. This, is further expected to fuel the demand for wound care therapy and also increase the adoption of disposable NPWT devices in the course of the forecast period.

North America to Lead Among All Regions

North America is expected to stay on the vanguard during the forecast period in the global disposable NPWT devices market with a share of 51.1% in the overall market. The U.S. is expected to emerge as the most lucrative nation in North America closely trailed by Western Europe and Asia Pacific excluding Japan. Based on product type, the market has been bifurcated into disposable NPWT with canister and disposable NPWT without canister. On the basis of end user, the market has been segmented into hospitals, clinics, and homecare settings.

Market Players to Concentrate on Product Differentiation

The top players in the market are focusing on product differentiation and expansion of consumer base in order to retain their position in the market. The leading players accounted for over 77% of the global market share in 2016. The players are Acelity (Kinetic Concepts, Inc.), Cardinal Health Inc., Smith and Nephew PLC., ConvaTec Inc., and Medela.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-6348

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Endoscopy Visualization System Market is estimated to expand from a value of US$ 1.3 Billion in 2021, to a value of US$ 2.2 Billion by 2028

Around 3/4^th share of the total revenue of endoscopy visualization systems landscape is accounted by Tier 1 players that are prominently focusing on cost effective product development

Leaders in endoscopy visualization systems landscape are also prioritizing innovative product launches, product portfolio extension, and strategic collaborations and mergers for an even stronger market footprint.
Tier 2 and Tier 3 companies, making up for the rest of market revenue, are particularly focusing on regional expansion – especially targeting developing Asian economies.

Prominently due to the paradigm shift to value based, sophisticated healthcare system and a mounting number of strategic mergers and acquisitions between leading medical device manufacturers, endoscopy visualization systems have been witnessing robust demand in recent years.

“With an ever growing demand for minimally invasive surgical procedures and growing availability of low-cost diagnostic procedures, we expect robust expansion of the global revenue through endoscopy visualization systems. While endoscopy visualization systems currently account for a billion dollar market globally, it is more likely that the endoscopy visualization systems landscape will observe over 7% year on year growth in 2019. Relatively undemanding FDA clearance guidelines is another strong factor pushing the prospects for endoscopy visualization systems in the near future,” says a senior research analyst at Future Market Insights.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-7596

Innovation of Endoscopy Visualization Systems Takes a Grand Leap beyond 3D Imaging

The 3D endoscope visualization system has been an impactful innovation in the endoscope visualization systems landscape. While 3D visualization technology offers a deeper view of the diagnostic area during endoscopic procedures, constant R&D efforts have directed the innovations to the latest – customized 3D visualization. The world’s first-ever endoscopy visualization system (by MedicalTek) has been recently launched that works on an easy-to-set and easy-to-alter imaging technique and offers an adjustable 3D perception to resultant endoscopic images.

Product Type Assessment: Adapting to the Trend of Minimally Invasive Surgery Demand, High-range Endoscopy Visualization Systems Remain the Top Seller

The FMI analyst explains that ever-growing demand for minimally invasive surgical procedures worldwide, it is quite clear that high-range endoscopy visualization systems will continue to bring in maximum revenue to the marketplace. With a current market value share of around 50%, high-range endoscopy visualization systems will be the highest selling type of EVS owing to favorable reimbursement policies and availability of advanced technology systems in this segment. Mid-range endoscopy visualization systems are also identified to capture a considerable market value share in 2019, demonstrating the year-on-year expansion of over 7%.

Diagnostic Area-wise Analysis: Maximum Opportunities Exist for GI Tract Endoscopy Visualization Systems

Recent statistical data published by American Society of Gastrointestinal Endoscopy (ASGE) indicates that among roughly 75 million endoscopic procedures annually performed at a global level, more than 65% are performed on the gastrointestinal tract, followed by the female reproductive tract. A considerable number of endoscopies are also performed through a small-sized incision with an objective to achieve least invasion. According to FMI’s projection for 2019, the year on year revenue growth will be around 7% in case of gastrointestinal tract endoscopy visualization systems, whereas that in case of small-sized incision procedures will be more than 7%.

Regional Outlook: Asia Pacific Becomes an Attractive Growth Platform for Manufacturers of Endoscopy Visualization Systems

While developing economies are constructing a lucrative base for the growth of endoscopy visualization systems landscape through changing demographics and an expanding patient pool, Future Market Insights offers exclusive insights on the same. An elevating number of endoscopy visualization systems predominantly for disorders of GI tract, female reproductive system, urinary tract, and respiratory system is encouraging the sales of endoscopy visualization systems in emerging Asian economies.

The FMI analyst says while unfolding the key attributes driving expansion of market within emerging regional territories, “While APEJ is at present the second largest market for endoscopy visualization systems after North America, Japan is also witnessing significant growth. This growth can be attributed to both, a healthy rate adoption of endoscopy visualization systems at hospitals, and impressively growing sales at specialty clinics”.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-7596

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Digital Mobile X-Ray Devices Market is likely to grow at a CAGR of 7.1% through 2016-2026

Future Market Insights, in its latest research, delivers key insights on the factors impacting the global digital mobile X-ray device market. According to the report, demand for digital mobile X-ray devices will continue to be fuelled by applications in orthopaedic- and chest-imaging. These two end-use applications accounted for 60% revenue share of the market in 2016.

Key Driving Factors

Increasing emphasis on diagnostic imaging services by various government bodies.
Increasing geriatric population – according to WHO, global geriatric population will reach 2 billion by 2050
Rising incidences of orthopaedic diseases and bone injuries – WHO estimates global prevalence of arthritis to between 0.3% and 1%
Contractual agreements and acquisitions by manufacturers
Increasing adoption of 3D medical imaging equipment, especially in the field of orthopaedics
Increase in the number of free standing imaging centers

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-990

Key Restraints

High cost of clinical trials and stringent regulations have remained longstanding challenges for manufacturers
Lack of inadequate imaging infrastructure in developing countries. High cost associated with initial set up and installation has been identified as a major restraint
Increasing pressure on the healthcare budget in the U.S. and rising awareness among patients about the potential health impact of radiation

By product type, mobile devices will continue to outsell handheld devices. In 2016, of the US$ 7.67 Bn worth of digital X-ray devices sold, 91.5% were mobile devices. However, owing to their small base size, demand for handheld digital mobile X-ray devices will grow at a higher CAGR than mobile devices.

Hospitals and radiology centers will continue to be the leading end-users of digital mobile X-ray devices globally. These two end-users collectively accounted for nearly 70% revenue share of the market in 2016. According to Future Market Insights’ research, these two end-use sectors will continue to account for the bulk of demand for digital mobile X-ray markets during the forecast period.

Region-wise Analysis and Forecast

North America is the largest market for digital mobile X-rays globally. Demand for digital mobile X-ray devices in the region is fuelled by strong sales in the U.S.
North America’s revenue share of the global market was nearly 32% in 2016. Owing to increasing demand in Asia Pacific excluding Japan (APEJ), Latin America, and Japan, North America will witness a slight dip in revenue share over the forecast period.
APEJ is projected to be the fastest growing market for digital mobile X-ray devices globally. The market in the region is expected to grow on account of high volume demand from China and India.
The Eastern Europe digital mobile X-ray market will witness slowest growth among all regions.

Competitive Landscape Analysis

Leading companies in the global digital mobile X-ray devices market are General Electric Healthcare Limited, Siemens AG, Esaote SpA, Hitachi Ltd., Koninklijke Philips N.V, Planmed OY, EOS Imaging, and Toshiba Medical Corporation. These leading companies are eyeing the lucrative APEJ market to capitalise on the growing opportunities.

Future Market Insights maintains a positive outlook on the global digital mobile X-ray market, projecting it to grow at 7.1% CAGR through 2026.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-990

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Clinical Oncology Next-generation Sequencing Market is projected to expand at a prolific CAGR of 16.3% between 2022 and 2029

Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology is one of the important applications of next-generation sequencing. It is an advanced and faster method of sequencing. Clinical oncology next-generation sequencing includes kits & reagents, services, sequencing platforms, and sequencing products. The kits and reagents used for sequencing are expected to witness significant growth in the overall market.

North America is expected to be a prominent region in the global clinical oncology next-generation sequencing market owing to the presence of well-developed healthcare infrastructure and numerous technological advancements in the region. North America and Europe are expected to witness a significant growth rate in the clinical oncology next-generation sequencing market.

Synthesis Sequencing Technology to Hold a Major Market Value Share

Based on the technology, the clinical oncology next-generation sequencing market has been segmented into pyro sequencing, sequencing by synthesis (SBS), and Single-Molecule Real-Time Sequencing (SMRT), nanopore sequencing, ligation sequencing, and reversible dye termination sequencing. Synthesis sequencing is however expected to hold a significant share in the clinical oncology next-generation sequencing market. Ion semiconductor sequencing is a method of DNA sequencing in which hydrogen ions are detected based on the polymerisation of DNA. Pyro-sequencing includes identifying the order of nucleotides in DNA based on the “sequencing by synthesis” principle, in which the sequencing is performed with the help of DNA polymerase. SBS is a technique used to determine the series of base pairs in DNA, which is also known as DNA sequencing.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-9543

There are various applications associated with clinical oncology next-generation treatment market. They include whole tumor genome sequencing, whole tumour exome sequencing, targeted tumour genome profiling, tumour transcriptome sequencing, tumour-normal comparisons, and other applications. Targeted tumor genome profiling is expected to hold a large share of the clinical oncology next-generation treatment market. On the basis of end user, the clinical oncology next-generation sequencing market has been segmented into hospital laboratories, clinical research organisations, diagnostic laboratories, and others. Clinical research laboratories are expected to hold a large revenue share in the clinical oncology next-generation sequencing market.

Apart from the factors driving the clinical oncology next-generation sequencing market, there are few factors that are likely to hinder the overall growth of the clinical oncology next-generation sequencing market, such as high costs associated with the establishment of sequencing platforms, low quality of outsourcing services, and inadequate availability of sequencing platforms in some regional markets. On the other hand, increasing biomedical research using clinical oncology, increasing government funding for life science projects, substantial decline in the prices of sequencing, and technological advancements in the field of sequencing are some of the major factors driving the growth of the clinical oncology next-generation sequencing market.

Tier 1 Companies Hold Nearly 3/5^th Share of Global Market Value

The report tracks some of the key companies operating in the clinical oncology next-generation sequencing market such as QIAGEN N.V., Thermo Fisher Scientific., Pacific Biosciences of California, Inc., F. Hoffmann-La Roche Ltd Oxford Nanopore Technologies, Ltd., Takara Bio, Inc., Illumina Inc., PerkinElmer Inc.and Agilent Technologies, Inc. Thermo Fischer Scientific, Oxford Nanopore Technologies Ltd., and Illumina are expected to hold a signficant share of the clinical oncology next-generation sequencing market. These first tier companies hold a share of approximately 60% in the clinical oncology next-generation sequencing market.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-9543

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Mucus Clearance Devices Market is expanding at a healthy 6.1% CAGR, the market size is projected to total US$ 847.0 Million by 2028

According to a recent market research study of Future Market Insights (FMI), more than 5 million units of mucus clearance devices were sold in 2021. The sales will reportedly increase by a robust 7.7% in 2022, as per the Y-o-Y growth calculated in the report. A majority of the demand for mucus clearance devices is accounted by home care settings, followed by hospitals.

HFCWO & OPEP Mucus Clearance Devices Selling Prominently

Consistently increasing prevalence of cystic fibrosis and COPD (chronic obstructive pulmonary disease) is a key factor responsible for the robust growth of the mucus clearance devices market. As per FMI’s analysis, cystic fibrosis generates the largest patient pool raising the demand for mucus clearance devices, accounting for almost half of the total sales. COPD also accounts for a significant volume share that roughly equates just-under a third of the mucus clearance devices market volume.

The demand for HFCWO (high-frequency chest wall oscillation) devices, which is more prominent in home care settings and hospitals, currently accounts for more than 1/3^rd of the total market volume. The report also highlights a notable share of the sales accounted by OPEP (oscillating positive expiratory pressure) devices, i.e. over 1/4^th of the total sales.

On other hand, stringent regulatory guideline by FDA for the approval of medical devices is likely to act as roadblock for the mucus clearance devices market. In addition, lack of awareness about the symptoms of cystic fibrosis and COPD in developing economies is another factor that is likely to hamper the growth of the mucus clearance devices market. Furthermore, the treatment rate for respiratory disorders is much lesser in low- and middle-income countries, which is also hampering the growth of the mucus clearance devices market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-9416

North America is the most prominent region in the global mucus clearance devices market, with over 2/5^th of the total market volume. North America’s market for mucus clearance devices is followed by Europe and East Asia, and the report points to attractive opportunities residing in India, Brazil, and South Africa.

Key Players in Mucus Clearance Devices Market Focusing on Online Distribution Channels

Leading distributers and suppliers operating in the global mucus clearance devices market are eyeing opportunities in the E-commerce sector. Online introduction and sales of innovative mucus clearance devices is being practiced by several companies to minimize costs associated with supply, distribution, and operation. Online availability also tends to attract a wider consumer base as it enables products comparison, according to research.

The rising focus of the leading medical device manufactures to launch novel mucus clearance devices such as SmartVest is expected to lead to the robust growth of the mucus clearance devices market. Smart mucus clearance devices that are being developed on a similar line of SmartVest have the smartphone-connectivity feature that allows doctors and respective hospitals to have ready access to real-time data, which can be further provided to telemedicine service providers. According to the report, such advanced technology enabled innovations will play a crucial role in boosting demand for mucus clearance devices in the near future.

Hill-Rom Inc., the global leader in mucus clearance devices landscape, currently represents an approximate 35% share in the market revenue. The report also profiles several other prominent players competing in the mucus clearance devices market, which include Allergan plc, Koninklijke Philips N.V., Respiratory Technologies, Inc., Smiths Medical, Electromed, Inc., Monaghan Medical Corporation, Dr. Burton Healthcare LLC, Actegy Limited, Westmed, Inc., International Biophysics Corporation, Thayer Medical, R. Cegla GmbH & Co. KG, Medical Acoustics LLC, VORTRAN Medical, and PARI Medical Holding GmbH.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-9416

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Surface Plasmon Resonance Market increasing at a decent CAGR of 6% over the forecast period of 2022- 2029

Increasing adoption of label-free detection techniques over labelled detection techniques is due to their cost-effective nature. Additionally, the availability of versatile products coupled with surface plasmon resonance to enhance the specificity of tests is an important factor that will bolster the demand for surface plasmon resonance. Imaging systems help in increasing throughput at a remarkable speed and with precise motion and consistency in report generation. Furthermore, the introduction of multifunctional products for improved outcomes is also expected to drive the growth of the surface plasmon resonance market over the forecast period.

The global surface plasmon resonance market is projected to reach a market value of US$ 770 Mn in 2019, increasing at a decent CAGR of 6% over the forecast period of 2019 – 2029.

“Increasing application of surface plasmon resonance in the field of drug discovery and medical imaging is contributing to the growth of the surface plasmon resonance market. Development of new technologies coupled with surface plasmon resonance, such as nanoparticle surface plasmon resonance and microfluidics, is playing an important role in the overall growth of the global surface plasmon resonance market.”

Key Takeaways of Surface Plasmon Resonance Market Study

The market share of imaging systems is evaluated to grow at a significant rate by the end of 2029, as these are the ideal solution for the analysis of label-free and multiplexed biomolecules.
Sales of surface plasmon resonance are envisaged to be higher in North America. Increasing adoption of imaging systems and biosensors in life science R&D is anticipated to boost the growth of the surface plasmon resonance market in the region.
Innovation while developing imaging software used in surface plasmon resonance for the analysis of kinetic parameters of biomolecular interactions is a key aspect for increasing the reproducibility of results. Companies are investing in R&D initiatives to introduce superior imaging devices with enhanced magnification, to observe the smallest deflection in the refractive index, thus aiding the growth of the surface plasmon resonance market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-962

Adoption of Label-free Detection Technique for Analysis of Biomolecules

Detection of biological analytes through their physical properties is difficult. As a result, researchers rely on the addition of some sort of label to one or more of the analytes that need to be studied. Inclusion of this label for increasing specificity and accuracy has increased the cost of reagents and assays. To reduce assay cost and complexity while providing more qualitative information through labelled detection, adoption of the label-free detection technique such as surface plasmon resonance has increased, and is expected to fuel the growth of the global surface plasmon resonance market during the forecast period. The label-free detection technique simplifies the procedure by reducing the time and effort required for the development of the assay. Thus, increasing adoption of label-free detection techniques over labelled detection is expected to boost the growth of the global surface plasmon resonance market.

Want more insights?

The surface plasmon resonance market report, a new study by Future Market Insights, opines on the evolution of the global surface plasmon resonance market from 2014–2018, and presents demand projections for 2019–2029, on the basis of product type (imaging systems, sensor systems, and reagents), application (drug delivery, material science, and biosensors), and end user (academic and research institutes, food and beverage industry, biopharmaceutical companies, CROs, and others), across seven prominent regions.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-962

SURFACE PLASMON RESONANCE MARKET TAXONOMY

The global surface plasmon resonance market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product Type

Imaging Systems
Sensor Systems
Reagents

Application

Drug Discovery
Material Science
Biosensors

End User

Academic & Research Institutes
Food & Beverage Industry
Biopharmaceutical Companies
CROs

Others

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-962

Region

North America
Latin America
Western Europe
Eastern Europe
APEJ
Japan
Middle East and Africa

Prescription Delivery Services Market to reach US$ 434.3 Million by 2030-end

Timely drug delivery is the cornerstone of an effective healthcare infrastructure. Rising prevalence of chronic and infectious ailments have accelerated production of prescription drugs, prompting vendors to develop effective distribution networks.

Advancements in consumer touch points and supply chains, including e-commerce, convenience stores and retail stores have greatly altered the prescription delivery services landscape. Advancements such as drone-based delivery and tracker based prescriptions are helping usher in smooth customer experience.

Furthermore, advanced prescription delivery systems have not only assisted in providing round-the-clock customer services but also helped manage dosage, therapy adherence and provide feedback to clinicians.

Prescription Delivery Services Market- Key Takeaways

Diabetic prescription drugs to hold major sway, poised to capture 36.7% market share by 2030
Ease of access to drugs addressing chronic conditions is slated to drive retail pharmacy growth to greater heights
North America to expand stupendously at a CAGR of 18.4% from 2020-2030, attributed to the presence of multiple convenience and pharmacy stores
Global prescription delivery services market to reach US$ 434.3 Mn by 2030-end

“Adoption of self-checkout kiosks and medicine dispensing machines shall enhance medicine purchasing experience of customers, permitting vendors to experience greater customer loyalty,” concludes the FMI analyst.

COVID-19 Impact Insights

The COVID-19 pandemic has generated fertile ground for the prescription delivery services market. The imposition of nationwide lockdowns to enforce social distancing have reduced footfalls across conventional pharmacies. This has compelled patients to rely on online retail platforms to avail their medicines.

Furthermore, heightened vulnerability of geriatrics suffering from co-morbidities to the coronavirus has necessitated stockpiling of essential medicines, thus keeping the need for prescription delivery services afloat throughout the pandemic’s duration. This panic buying behavior shall usher in an 80% y-o-y growth.

Growth is especially anticipated to be robust across the U.S, China and India, countries with the highest rates of infections. Collectively accounting for 40% of the global infection rate, these countries have witnessed an unprecedented increase in hoarding prescription medicines by individual households. This shall continue until the latter-half of 2021.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-12534

Market Witnessing Entry of e-Commerce Players

The Prescription Delivery Service Market is witnessing entry of e-Commerce, pharmacy and retail chains, albeit at a local or regional level. Technological developments, new product launches and collaborations characterize some critical expansion strategies of market players.

Some of the key players in the Prescription Delivery Service Market are: Walgreens Co., Walmart Stores Inc., CVS Health, Giant Eagle Inc., Express Scripts Holding Company, Ali Health and Kroger Co. to name a few.

Besides these established players, several startup companies are also emerging as potential game changers in the industry. These include NetMeds, Kfyao, Capsule, Myra Medicines, NURX, MedAvail, Zipdrug, Insightfil and ScriptDrop to name a few.

Walgreens, a prominent retail pharmaceutical distributor, has a robust presence in the global prescription delivery services market. The company offers refills, auto refills, drug information and home delivery services.

In 2017, the company acquired Rite Aid for a sum of US$ 5.2 billion, resulting in the merger of two of the United States’ three largest pharmacy chains.

More Insights on the Prescription Delivery Services Market

A recent market study published by Future Market Insights on the Prescription Delivery Services Market includes global industry analysis for 2015-2019 & opportunity assessment for 2020-2030, and delivers a comprehensive assessment of the most important market dynamics. The report has been segmented on the basis of disease indication (therapeutic drugs (diabetes, hypertension & cholesterol disorders), wellness supplements, OTC drugs and diagnostic drugs) and distribution channel (pharmacy stores, healthcare institutions, clinics and research institutions) across seven geographies (North America, Latin America, Europe, South Asia, East Asia, Oceania and MEA).

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-12534

Prescription Delivery Services Market Segmentation

Disease Indication

Therapeutic Drugs
Diabetes
Hypertension
Cholesterol Disorders
Wellness Supplements
OTC Drugs
Diagnostic Kits

Distribution Channel

Pharmacy Stores
Retail Pharmacy
Drug Stores
Healthcare Institutions
Clinics
Research Institutes

Region

North America (U.S & Canada)
Latin America (Brazil, Mexico & Rest of Latin America)
Europe (Germany, France, Italy, U.K, Spain, BENELUX, Russia & Rest of Europe)
South Asia (India, Malaysia, Thailand, Indonesia & Rest of South Asia)
East Asia (China, Japan & South Korea)
Oceania (Australia & New Zealand)
Middle East & Africa (GCC, Northern Africa, South Africa & Rest of MEA)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-12534

Microneedle Drug Delivery Systems Market Key Players – 3M Company, Becton, Dickinson and Company, Zosano Pharma Corporation, Raphas co. ltd., Nanopass Tech

Emerging applications of microneedle drug delivery systems are expected to fuel their demand over the next decade. According to a recent report published by Future Market Insights (FMI), the global microneedle drug delivery systems market will grow at a CAGR of 6.6% between 2020 and 2030. The market is witnessing surging demand in the field of pharmacy and cosmetics.

The rising incidence of diseases such as cancer, diabetes, migraine, and others and the need to accurately administer medications are driving the market. Additionally, the demand for minimally invasive and painless treatment methods is expected to bode well for the market.

The report uncovers hidden growth opportunities. It also highlights potential threats to the market players. Some of the key takeaways from the report are highlighted below.

Key Takeaways from the Report

Solid microneedles are expected to lead the market during forecast period of 2020-2030 among product type
Hospitals are the leading end users of microneedle drug delivery systems, with specialty clinics gaining popularity.
Specialty clinics are expected to grow at an accelerated rate as one of the key end users of microneedle drug delivery systems
North America is the largest market for microneedle drug delivery systems. Along with Europe, it is expected to cover more than 70% of the market by end of 2030.
East Asia is expected to be the fastest growing regional market during the next decade.

“Companies operating in the market are leaving no stone unturned to introduce innovations. Some have even tied up with leading solutions provider to commercialize their innovations once approved. This is expected to pave way for the market’s growth in the near future” said a lead Analyst at FMI.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2750

Covid 19 Restricting Pace of Growth

The onset of pandemic has disturbed the entire business ecosystem. With productions coming to a halt and supply chains disrupted due to lack of transport, manufacturers of microneedle drug delivery systems are impacted in a big way.

Also, because of several restrictions by governments like social distancing, doctors and practitioners are choosing to avoid any surgical treatments which are not absolutely and immediately necessary.

Furthermore, cosmetic field which is another major user of microneedle drug delivery systems is also impacted as almost all treatments under their umbrella are considered to be not urgent.

The key market players in microneedle drug delivery systems market include the

3M Company, Becton, Dickinson and Company, Zosano Pharma Corporation, Raphas co. ltd., Nanopass Tech, Corium International, Inc., Valeritas, Inc., Nitto Denko Corporation, Microdermics, Inc., TheraJect Inc., Vaxxas Pty Ltd., Endoderma Ltd., QuadMedicine, SNvia Co., Ltd., Small Lab and AdminMed Nano BioSciences LLC

Consolidating their positions through mergers, acquisitions and new product launches, global microneedle drug delivery systems market players rely heavily on new product innovation and differentiation for gaining an edge over their competitors.

The market is poised to grow during the forecast period owing to the increasing cases of diseases and needle phobia among patients. However, changing regulatory dynamics are expected to affect the growth of microneedle drug delivery systems market in the future.

For instance, Zosano Pharma’s clinical trial of zolmitriptan with microneedle drug delivery system was stopped by U. S. Food and Drug Administration because inconsistencies were found in the drug delivery.

To Know More about Heat induction Cap liner Market:

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global microneedle drug delivery systems market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on microneedle drug delivery systems market on the basis of product type such as solid microneedles, hollow microneedles and dissolving microneedles. Based on end-user such as hospitals, ambulatory centers, specialty clinics, academic institutes and research institutes across seven major regions

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2750

Key Segments

Product Type

Solid Microneedles
- Silicon
- Metal
- Polymer
Hollow Microneedles
Dissolving Microneedles

End User

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Academic Institutions
Research institutes

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-2750

Region

North America
Latin America
Europe
East Asia
South Asia
Oceania
MEA

PD-L1 Biomarker Testing Market By Product Type, By End User and By Region: Industry Analysis, Revenue Opportunity, Competitive Analysis

As the prevalence of lung cancer, melanoma, and renal cell carcinoma continues to soar worldwide, the adoption of PD-L1 biomarker testing is expected to grow at a healthy pace in the years to come, says Future Market Insights (FMI) in its new market study. Moreover, the report forecasts that the global PD-L1 biomarker testing market will grow in value at a stellar CAGR of 13.1% between 2020 and 2030.

The report opines that the outbreak of COVID-19 is likely to create short-term fluctuations on the supply side due to pandemic-related issues such as workforce shortages and disruptions of delivery networks. Similarly, a steep decline in the number of tests has been observed during the pandemic, and this is expected to further decelerate the demand for PD-L1 biomarker testing.

The report primarily attributes the growth of the market to the increasing incidence of cancers, especially lung and skin, coupled with the development of advanced diagnostic kits and assays.

Likewise, rising awareness regarding the availability of testing methodology such as immunohistochemistry-based assays and Enzyme-linked Immunoassay (ELISA) based detection will continue to impel the adoption of PD-L1 biomarkers in the forthcoming years.

Key Takeaways

The global PD-L1 biomarkers testing market is expected to surge past valuation of US$ 2.05 Bn by the end of the forecast period.
PD-L1 SP142 assay kits will remain the most popular products among end-users, capturing nearly half of the market value, owing to high efficiency in detecting cancer tumors.
Non-small cell lung cancer and melanoma are cumulatively expected to hold more than 50% of the total market value on the back of the soaring prevalence of these diseases.
By end-use, PD-lL1 biomarker testing finds the majority of applications in hospitals, which is expected to account for over 60% of market value.
North America will spearhead the regional landscape through the forecast period, accounting for more than 50% of the global market value.
Europe is poised to remain the second most lucrative region, holding nearly 1/3rd of market value.

“Market players are directing their efforts towards improving the accessibility of these products and are marking them cost-effective to ensure wide-scale adoption,” remarks FMI analyst.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5897

COVID-19 Impact on PD-L1 Biomarker Testing Market

The COVID-19 pandemic has created disruptions across the healthcare technology landscape and has resulted in a shifting preference among manufacturers towards essential technologies and treatments. Furthermore, although PD-L1 biomarker testing is used to test severe diseases such as cancer, a reduced number of screenings is adversely impacting the demand for testing.

For instance, according to trends observed by Cancer Research Network, screening rates of melanoma plummeted by approximately 50% in the UK in the past few months. Likewise, in the US, the number of tests conducted to detect non-small cell lung cancer fell by 30% in March as compared to February. As patients reschedule or skip regular screenings, this is creating a downtrend in demand for PL-D1 biomarker testing.

However, considering the severity of these diseases, the need for testing will swiftly arise in the future, ensuring that the market’s growth trajectory remains intact.

Who is Winning?

Key players operating in the market are focusing on enhancing existing product designs and developing novel products with increased accuracy. Moreover, traditional growth strategies such as acquisitions and mergers have been identified as strategies adopted by players to strengthen their foothold in the competitive landscape.

In January 2019, Abcam Plc acquired Calico Biolabs with an objective to expand its custom monoclonal production service capabilities.
In December 2018, NeoGenomics, Inc. acquired Genoptix, Inc. to improve its oncology diagnostic services.

FMI’s report includes profiles of some of the most prominent names in the market including F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., NeoGenomics Laboratories, Inc, HalioDx and Abcam plc. among others.

To Know More About PD-L1 Biomarkers Market

A new market research report published by Future Market Insights (FMI) on the global PD-L1 biomarkers market offers an executive-level blueprint of the market. It offers insights into demand trends and provides analysis of opportunities over the forecast period, 2020-2030. The report examines the market through four different segments – product, indication, end-use, and region. The report also provides extensive assessment of pricing by different key market dynamics, life cycle analysis, and technologies that are being deployed in the supply and product adoption across several end-use industries.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5897

Key Segments

Product:

PD-L1 22C3 Assay Kit
PD-L1 28-8 Assay Kit
PD-L1 SP142 Assay Kit
PD-L1 SP263 Assay Kit

Indication:

Non-small Cell Lung Cancer (NSCLC)
Melanoma
Renal Cell Carcinoma
Gastrointestinal Tract Malignancies
Ovarian Cancer
Hematological Malignancies

End-user:

Hospitals
Diagnostic Laboratories
Specialty Clinics

Region:

North America
Latin America
Europe
South Asia
Oceania
East Asia
Middle East and Africa

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-5897